Details About Generic Salt ::  Bepridil

Main Medicine Class:: Calcium channel blocker   

(BEH-prih-dill)

Vascor

Tablets: 200 mg

Tablets: 300 mg

Class: Calcium channel blocker

 Indications Treatment of chronic stable angina in patients who fail to respond optimally to, or who are intolerant of, other antianginal agents.

 Contraindications History of serious ventricular arrhythmias; sick sinus syndrome; second- or third-degree block; uncompensated cardiac insufficiency; hypotension (less than 90 mm Hg systolic); congenital QT interval prolongation; concurrent drugs that prolong the QT interval; hypersensitivity to bepridil.

 Route/Dosage

ADULTS: PO Start with 200 mg once daily then, after 10 days, dosage may be adjusted upward depending on the response (max, 400 mg/day).

 Interactions

Anti-arrhythmic agents (eg, quinidine, procainamide), cardiac glycosides, cisapride, tricyclic antidepressants (eg, thioridazine), sparfloxacin, ritonavir

May increase the risk of serious adverse effects or life-threatening cardiac arrhythmias (including torsades de pointes).

 Lab Test Interferences None well documented.

 Adverse Reactions

CARDIOVASCULAR: Palpitations; sinus tachycardia; sinus bradycardia; hypertension; vasodilation; edema; ventricular premature contractions; ventricular tachycardia; prolonged QT interval. CNS: Insomnia; dizziness; tremor; hand tremor; nervousness; drowsiness; fainting; vertigo; akathisia; insomnia; depression; anxiousness; adverse behavior. DERMATOLOGIC: Rash; sweating; skin irritation. EENT: Tinnitus; rhinitis; pharyngitis; blurred vision; taste change. GI: Nausea; dyspepsia; GI distress; dry mouth; anorexia; diarrhea; constipation; flatulence; gastritis; increased appetite. GU: Loss of libido; impotence. HEPATIC: Abnormal LFTs; increased ALT. RESPIRATORY: Dyspnea; cough. OTHER: Asthenia; flu-like syndrome; fever; pain; myalgic asthenia; superinfection; arthritis.

 Precautions

Pregnancy: Category C. Lactation: Excreted in breast milk. CHILDREN: Safety and efficacy not established. ELDERLY: Select dose with caution, reflecting greater frequency of decreased hepatic, renal, or cardiac function and comorbidity. Renal impairment: Risk of toxicity is increased. QT interval: The QT and QTc interval are prolonged in a dose-related fashion, which may cause serious ventricular arrhythmias (including torsades de pointes). Hematologic: Agranulocytosis has been associated with bepridil use. Pulmonary infiltration: Noninfective, noncardiogenic pulmonary interstitial infiltrates, including cases of pulmonary fibrosis, have been associated with bepridil use.

PATIENT CARE CONSIDERATIONS

 Administration/Storage

• Administer prescribed dose once daily, with or without food. Administer with food if GI upset occurs.
• Store tablets at controlled room temperature (59° to 77°F). Protect from light.

 Assessment/Interventions

• Obtain patient history, including drug history and any known allergies. Note history of the following: allergy to bepridil, serious ventricular arrhythmias, sick sinus syndrome, second- or third-degree AV block, hypotension (less than 90 mm Hg systolic), uncompensated CHF, congenital QT interval prolongation, concomitant use of other drugs that prolong the QT interval, severe liver or kidney dysfunction.
• Ensure that serum potassium and ECGs are monitored periodically.
• Monitor patient for GI, CNS, and general body side effects. Inform health care provider if noted and significant.
• Implement safety precautions if patient experiences dizziness.

OVERDOSAGE: SIGNS & SYMPTOMS   Hypotension, high-degree AV block, ventricular tachycardia

 Patient/Family Education

• Explain name, dose, action, and potential side effects of drug.
• Advise patient to take once daily as prescribed, without regard to meals.
• Advise patient to take with food if GI upset occurs.
• Advise patient to try to take each dose at about the same time each day.
• Inform patient that drug helps control, but not does cure angina, and to continue taking drug as prescribed even when angina symptoms are not present and to keep sublingual nitroglycerin available for use if needed.
• Instruct patient to continue to take other antianginal medications (eg, beta blockers and daily nitrates) as prescribed by health care provider.
• Caution patient not to change the dose or stop taking unless advised by health care provider.
• Instruct patient to immediately report fainting or loss of consciousness, palpitations, or dizziness to health care provider.
• Instruct patient to notify health care provider if angina symptoms worsen or begin to occur more frequently or if their use of sublingual nitroglycerin suddenly increases.
• Instruct patient to continue taking potassium supplements or potassium-sparing diuretics as prescribed by health care provider.
• Instruct women to notify health care provider if pregnant, planning on becoming pregnant, or breastfeeding.
• Caution patient to not take any prescription or OTC medications or dietary supplements unless advised by health care provider.
• Advise patient that follow-up visits and lab tests, including ECGs and serum potassium levels, will be required to monitor therapy and to be sure and keep appointments.

Drugs Class ::

Indications for Drugs ::

 Indications Treatment of chronic stable angina in patients who fail to respond optimally to, or who are intolerant of, other antianginal agents.

Drug Dose ::

 Route/Dosage

ADULTS: PO Start with 200 mg once daily then, after 10 days, dosage may be adjusted upward depending on the response (max, 400 mg/day).

Contraindication ::

 Contraindications History of serious ventricular arrhythmias; sick sinus syndrome; second- or third-degree block; uncompensated cardiac insufficiency; hypotension (less than 90 mm Hg systolic); congenital QT interval prolongation; concurrent drugs that prolong the QT interval; hypersensitivity to bepridil.

Drug Precautions ::

 Precautions

Pregnancy: Category C. Lactation: Excreted in breast milk. CHILDREN: Safety and efficacy not established. ELDERLY: Select dose with caution, reflecting greater frequency of decreased hepatic, renal, or cardiac function and comorbidity. Renal impairment: Risk of toxicity is increased. QT interval: The QT and QTc interval are prolonged in a dose-related fashion, which may cause serious ventricular arrhythmias (including torsades de pointes). Hematologic: Agranulocytosis has been associated with bepridil use. Pulmonary infiltration: Noninfective, noncardiogenic pulmonary interstitial infiltrates, including cases of pulmonary fibrosis, have been associated with bepridil use.

Drug Side Effects ::

 Adverse Reactions

CARDIOVASCULAR: Palpitations; sinus tachycardia; sinus bradycardia; hypertension; vasodilation; edema; ventricular premature contractions; ventricular tachycardia; prolonged QT interval. CNS: Insomnia; dizziness; tremor; hand tremor; nervousness; drowsiness; fainting; vertigo; akathisia; insomnia; depression; anxiousness; adverse behavior. DERMATOLOGIC: Rash; sweating; skin irritation. EENT: Tinnitus; rhinitis; pharyngitis; blurred vision; taste change. GI: Nausea; dyspepsia; GI distress; dry mouth; anorexia; diarrhea; constipation; flatulence; gastritis; increased appetite. GU: Loss of libido; impotence. HEPATIC: Abnormal LFTs; increased ALT. RESPIRATORY: Dyspnea; cough. OTHER: Asthenia; flu-like syndrome; fever; pain; myalgic asthenia; superinfection; arthritis.

Drug Mode of Action ::  

Drug Interactions ::

 Interactions

Anti-arrhythmic agents (eg, quinidine, procainamide), cardiac glycosides, cisapride, tricyclic antidepressants (eg, thioridazine), sparfloxacin, ritonavir

May increase the risk of serious adverse effects or life-threatening cardiac arrhythmias (including torsades de pointes).

Drug Assesment ::

 Assessment/Interventions

• Obtain patient history, including drug history and any known allergies. Note history of the following: allergy to bepridil, serious ventricular arrhythmias, sick sinus syndrome, second- or third-degree AV block, hypotension (less than 90 mm Hg systolic), uncompensated CHF, congenital QT interval prolongation, concomitant use of other drugs that prolong the QT interval, severe liver or kidney dysfunction.
• Ensure that serum potassium and ECGs are monitored periodically.
• Monitor patient for GI, CNS, and general body side effects. Inform health care provider if noted and significant.
• Implement safety precautions if patient experiences dizziness.

Drug Storage/Management ::

 Administration/Storage

• Administer prescribed dose once daily, with or without food. Administer with food if GI upset occurs.
• Store tablets at controlled room temperature (59° to 77°F). Protect from light.

Drug Notes ::

 Patient/Family Education

• Explain name, dose, action, and potential side effects of drug.
• Advise patient to take once daily as prescribed, without regard to meals.
• Advise patient to take with food if GI upset occurs.
• Advise patient to try to take each dose at about the same time each day.
• Inform patient that drug helps control, but not does cure angina, and to continue taking drug as prescribed even when angina symptoms are not present and to keep sublingual nitroglycerin available for use if needed.
• Instruct patient to continue to take other antianginal medications (eg, beta blockers and daily nitrates) as prescribed by health care provider.
• Caution patient not to change the dose or stop taking unless advised by health care provider.
• Instruct patient to immediately report fainting or loss of consciousness, palpitations, or dizziness to health care provider.
• Instruct patient to notify health care provider if angina symptoms worsen or begin to occur more frequently or if their use of sublingual nitroglycerin suddenly increases.
• Instruct patient to continue taking potassium supplements or potassium-sparing diuretics as prescribed by health care provider.
• Instruct women to notify health care provider if pregnant, planning on becoming pregnant, or breastfeeding.
• Caution patient to not take any prescription or OTC medications or dietary supplements unless advised by health care provider.
• Advise patient that follow-up visits and lab tests, including ECGs and serum potassium levels, will be required to monitor therapy and to be sure and keep appointments.

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.